We examined chemotaxis of human plasma cells (PCs) in response to extracellular matrix proteins (ECMs) in the human PC c e l l lines FRQds and OPM-lds. The FR4ds cells expressed /SI+, p3-, a2-, a3-. a4+. a5+, a6+, and a v + integrins, whereas the OPM-lds cells expressed /Sl+, p3-, a2-, a3+, a4+, as-, &+, and m + . Fibronectin (FN) and laminin ILN) promoted the chemotaxis of the PCs. An inhibitory assay with anti-integrin monoclonal antibodies (MoAbs) showed that antLa4 MoAb partially inhibited the chemotaxis of FR4ds and completely inhibited the chemotaxis of OPM-lds.
UMAN PLASMA CELL (PC) neoplasias have been divided into three clinico-pathologic types. The first and most common type is multiple myeloma, the second type is plasma cell leukemia, and the third type is plasmacytoma. ' In multiple myeloma, malignant plasma cells are preferentially localized in the bone marrow. Circulating tumor cells in the peripheral blood of patients with nonleukemic multiple myeloma have been suggested from phenotypic and genotypic studies. 24 Uchiyama et a15 have shown that human myeloma-derived cell lines specifically adhere to the marrow extracellular matrix (ECM) protein fibronectin through a401 integrin (VLA-4) and an RGD peptide-dependent mechanism. They speculated that the adhesion may contribute to the localization of myeloma cells in the bone marrow. They have also shown that the cell lines they studied lacked the VLA-6 laminin receptor, which is commonly expressed on the surface of myeloma cells freshly isolated from patients with multiple myeloma.6 They speculated that, because the basal lamina is composed mainly of laminin, the lack of VLA-6 does not induce their transit into the extravascular space. However, they have also suggested that the results obtained from myeloma cell lines lacking VLA-6 may not reflect either the cell surface phenotype or the biology of myeloma in vivo.
Fibronectin (FN) and laminin (LN) induce not only the adherence and spread of cells' but also their migration and chernotaxk8"' It is important to examine the migratory properties of plasma cells after the induction by FN and LN to understand the localization of malignant plasma cells in the bone marrow. The expression of the adhesion molecules and the adherence properties of malignant plasma cells to ECMs have been intensively st~died,5.~."'~ but cell movement toward ECMs and whether malignant plasma cells show any chemotactic activity toward ECM proteins such as FN and LN have not been investigated.
Adhesion molecules of at least the integrin, cadherin,16 Ig gene," selectin," and CD44 families" have been defined. The integrin family is important because it regulates adhesion and migration.'','' Integrins, which consist of ap heterodimers, are subdivided into subfamilies based on their p subunits. According to this classification, VLA proteins represent the @l integrin subfamily consisting of l 1 different structures": plal through a9, aL, and (YV. In this study, we clarified the chemotactic properties of malignant plasma cells using the PC cell lines FR4ds and OPM-Ids expressing p 1 integrins, the expression profiles of which are similar to those of myeloma cells freshly isolated from patients with multiple myeloma.
MATERIALS AND METHODS

Cell lines.
The human plasmacytoma cell line, FR4, has been e~tablished.'~ During the culture of FR4, the shape of the cells changed, exhibiting a "spreading" appearance. The production of Ig and amylase was preserved. Karyotype analysis showed that the cells with the "spreading" phenotype had essentially the same chromosomal abnormalities as FR4 (data not shown), suggesting that these cells were derived from FR4. Therefore, we renamed the cell line FR4ds. ' OPM-l is a myeloma cell line established by Katagiri et aLZ4 As described in their original report, OPM-1 also has a tendency to spread. During cultivation in the same culture bottle, about 30% of the cells exhibited a spreading morphology. We renamed the line OPM-lds. We used FR4ds and OPM-lds for chemotaxis assays.
Reagents. We examined the surface antigen expression of the two cell lines using the monoclonal antibodies (MoAbs) listed in Table 1 . Anti-01 integnn MoAb was purchased from Coulter (Hialeah, FL). Anti-03 integrin MoAb was purchased from Biodesign International (Kennebunkport, ME). Anti-a2 integrin MoAb, antia 4 integrin MoAb, anti-a5 integrin MoAb, and anti-a6 integrin MoAb were purchased from Immunotech S.A. (Marseille, France). Anti-a3 integrin MoAb and anti-av integrin MoAb were purchased from Cosmo Bio (Tokyo, Japan).
Phenotypic analysis of cell lines. The reactivities of the cell lines with the MoAbs were assessed by indirect immunofluorescence assays and a FACScan (Becton Dickinson, Montain View, CA).
FN and LN. Serum fibronectin was purchased from Cosmo Bio. Laminin was purchased from Takara Shuzo (Kyoto, Japan). RPMI-1640 containing FN and LN was used in the chemotaxis assays.
Chemotaxis assay. The chemotactic activity of the malignant plasma cells was examined by Boyden's method, with some modification. Briefly, cells suspended in RPMI-1640/10% fetal calf serum (FCS) were washed twice in Hanks Balanced Saline Solution (HBSS) and resuspended in RPMI-1640 at a cell concentration of 5 X 10' cellslml. These cells were placed in the upper compartment of a 48-well microchemotaxis chamber (Neuroprohe, Rockville, MD). 25 The lower compartment that contained the chemoattractant was separated from the upper compartment by a Nuclepore, polyvinylpyrrolidone (PVP)-free polycarbonate filter (Neuroprobe). In a preliminary study, we determined that a filter pore size of 8 pm and a cultivation period of 6 hours were suitable for assessing chemotaxis in these plasma cell lines. After incubation at 37°C for 6 hours in a humidified 5% CO2 incubator, the filters were removed from the chambers, stained with May-Giemsa, and counted under a microscope at high power magnification. Data represent the mean 2 1 SD of the number of cells per high power field (15 fields counted) on triplicate filters.
Checkerboard assay. We determined whether the migration was caused by chemotaxis or random locomotion by means of a checkerboard assay. To measure chemotactic and chemokinetic activities, we used FN and LN at different concentrations in positive and negative gradients and in the absence of a gradient.
We performed standard statistical analyses using the two-sample t-test to distinguish chemotactic from chemokinetic activities. The number of cells that migrated when the ECM concentration was A pg/mL in the upper well and B pg/mL in the lower well was abbrevi- Using the anti-LN receptor (antie3 integrin and anti-a6 integrin) MoAbs, we estimated the contribution of each LN receptor required for LN-induced chemotaxis. A concentration of 40 pg/mL of LN in RPMI-1640 was optimal, judging from the results of the checkerboard assay. MoAbs (10 pg/mL) were added to the upper compartment of the chemotaxis chamber at the start of the incubation. We used the following class-matched control antibodies: mouse IgGl for anti-@l MoAb, anti-a3 MoAb, anti-a4 MoAb, and anti-av MoAb; mouse IgG2 for antiLa5 MoAb; and rat IgG2a for anti-a6 MoAb.
Inhibition of chemotaxis by RGD peptide. We examined the inhibitory effect of a synthetic GRGDSP peptide that corresponds to the cell attachment site of FN (Bachem California, CA). The GRGDSP peptide was added to the upper compartment of the chemotaxis chamber with or without anti-a4 integrin MoAb. The concentration of the peptide was 0.4 mmol/L. The Concentration of FN in the lower compartment of the chemotaxis chamber was 0.09 pmoll L. We used GRGESP (Bachem California) as a negative control.
Statistical analysis. Statistical analysis was performed using the two-sample t-test. A P value of less than .01 was considered signifi- 
RESULTS
Surface markers.
The results of the reactivities with antipl, p3, a2, a3, a4, a5, a6, and a v integrin MoAbs are shown in Table 2 . FR4ds expressed PI, a4, a5, a6, and a v integrins, whereas OPM-lds expressed Dl, a3, a4, a6, and a v integrins. Therefore, these two cell lines differed in the expression of a 5 and a3 integrins. The contribution of FN receptor subunits a4, a.5, and av integrins to the chemotaxis induced by FN. We addressed the relative importance of the FN receptors in chemotaxis by an inhibition assay using antie4 integrin MoAb, anti-a5 integrin MoAb, and anti-av integrin MoAb (Fig 3) . In both FR4ds and OPM-Ids, anti-p1 integrin MoAb almost completely inhibited the chemotaxis induced by FN. MoAb partially inhibited the chemotaxis of FR4ds expressing a 4 and a 5 integrins but completely inhibited the chemotaxis of OPM-1ds expressing a 4 integrin alone. These results indicated that VLA-4 is an essential receptor for the chemotaxis induced by FN. We next investigated the role of VLA-5. In FR4ds, anti-a5 MoAb alone did not inhibit chemotaxis. This result indicated that the binding of FN to VLA-5 alone does not mediate chemotaxis. However, anti-a5 MoAb significantly enhanced the blocking effect of anti-a4 MoAb in FR4ds: the simultaneous use of a n t i 4 MoAb with anti-a4
FR4ds and OPM-lds. MoAb completely blocked the chemotaxis of FR4ds. We also examined the effect of mouse IgG1, used as a classmatched control antibody for a n t i d MoAb. The control antibody had no effect when added with anti-a4 MoAb. This result indicated that the effect of the a n t i d MoAb is specific. The residual number of chemotactic cells in the presence of anti-a4 MoAb plus anti-a5 MoAb (9% of the control) was similar to that with the anti-p1 MoAb alone (10% of the control). Anti-av MoAb did not inhibit the chemotaxis of FR4ds induced by FN when it was added alone or with anti-a4 MoAb. This finding indicated that avp1 does not participate in the chemotaxis of FR4ds induced by FN.
The contribution of an RGD peptide to chemotaxis induced by FN. Neither a GRGDSP peptide corresponding to the cell attachment site of FN nor the control peptide GRGESP alone significantly inhibited the chemotaxis of FR4ds induced by FN (Fig 4) . GRGDSP significantly decreased the residual chemotaxis of FR4ds when added with anti-a4 integrin MoAb, whereas GRGESP did not. There are five types of integrins (&l, a v p l , aIIbp3, avp3, and avp5) that recognize the RGD sequence." Among these, a 5 p l and a v p l are expressed on the surface of FR4ds. The expression of avp5 was not determined in this study. However, the anti-av MoAb results described above indicated that av integrin does not significantly participate in the chemotaxis of FR4ds induced by FN. Our data indicate that it is unlikely that the GRGDSP peptide binds to either avo1 or avp5 to effect the inhibition of chemotaxis. Therefore, it seems likely that the chemotactic inhibitory effect of the GRGDSP peptide is caused by its binding to VLA-5. The complementary effect of VLA-5 toward that of VLA-4 was completely abolished by the GRGDSP peptide, demonstrating a novel complementary role of VLA-5.
Contribution of LN receptor subunits to chemotaxis induced by LN. In both FR4ds and OPM-lds, anti-p1 integrin MoAb almost Completely inhibited the chemotaxis induced by LN (Fig 5) . We determined the relative importance of VLA-3 and -6 of the LN receptors in chemotaxis by means of an inhibition assay using anti-a3 integrin MoAb and anti-a6 integrin MoAb. The result showed a contribution by these two LN receptors. The chemotaxis toward LN in FR4ds was completely dependent on VLA-6. In contrast, the chemotaxis of OPM-lds toward LN was dependent on both VLA-3 and VLA-6. The involvement of VLA-3 was more statistically significant than that of VLA-6. The residual chemotaxis after blocking with anti-a3 MoAb was significantly inhibited by anti-a6 MoAb. These results suggested that the binding of LN to VLA-6 can mediate chemotaxis. Thus, VLA-6 may be an essential receptor for the chemotaxis induced by LN.
DISCUSSION
We showed for the first time that the plasma cell lines FR4ds and OPM-lds showed chemotactic activity toward FN and LN. These chemoattractants are ECMs. For personal use only. on August 30, 2017. by guest www.bloodjournal.org From with myeloma/plasmacytoma/plasma cell leukemia, whereas VLAJ is expressed in the malignant cells of few number of patients with myeloma." Kawano et a l Z 7 have reported that VLA-4+/5-cells comprise the positive growth fraction, whereas VLA-4+/5+ cells make up the nongrowth fraction.
VLA-4 is expressed on the malignant cells of all patients
However, the biologic significance of the expression of VLA-5 in plasma cell malignancies is unknown. The FR4ds cells had the rare phenotype of VLA-4+ and 5+, whereas the OPM-lds cells had a phenotype similar to that of the majority of plasma cells, namely VLA-4+.
The chemotaxis of OPM-lds toward FN was completely dependent on VLA-4. The chemotaxis of FR4ds was dependent primarily on VLA-4. The involvement of VLA-5 in FR4ds is unusual and anti-a5 MoAb alone had no effect. We addressed the relative importance of these L N receptors in chemotaxis with an inhibition assay using anti-a3 MoAb and anti-a6 MoAb. The assay showed a hitherto unknown contribution of these two LN receptors. Because LN induced chemotaxis in FR4ds, with the phenotype of VLA-3-and 6+, and in OPM-lds, with the phenotype of VLA-3' and 6+, the chemotaxis toward LN appeared to be primarily dependent on VLA-6. Because the VLA-3+ OPM-lds exhibited more chemotactic activity than the VLA-3-FR4ds, and because anti-a3 MoAb inhibited more chemotaxis than antia6 MoAb in OPM-lds, VLA-3 may regulate the sensitivity of the chemotaxis mediated by the binding of LN to VLA-6. Our data suggested that both plasmacytoma and myeloma cells that are commonly positive for VLA-6 can pass through the basement membrane, which is composed mainly of LN, to the extravascular space.
Our results suggested two implications for the localization of neoplastic plasma cells including myeloma. One is that /?l integrins on the surface of plasma cells not only bind to ECMs, resulting in their localization, but also help in their migration toward ECMs before binding and localizing to the ECMs. Another important implication is that the distribution of plasma cells in human tissues might be dependent on at least two factors: the LN and FN concentrations and the expression profiles of VLA-3 and -6 and VLA-4 and -5. W e found some evidence that the bone marrow microenvironment suppresses the chemotactic activity of plasma cells (unpublished observations). It is possible that this factor plays some role in the localization of myeloma cells in the bone marrow. We are now purifying the substance(s) mediating this inhibitory effect.
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